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BACKGROUND: Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-
ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse
and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3
inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid
leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in
patients with relapsed or refractory acute myeloid leukaemia.
METHODS: We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and
cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically
documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to
myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0-2 into two predefined, independent cohorts: patients who were
aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year
after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or
refractory disease following salvage chemotherapy or haemopoietic stem cell
transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10%
were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-
ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17
patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms
above baseline in some of these patients. Subsequently, doses were amended for all
patients to 135 mg per day for men and 90 mg per day for women. The co-primary
endpoints were the proportion of patients who achieved a composite complete remission
(defined as complete remission + complete remission with incomplete platelet
recovery + complete remission with incomplete haematological recovery) and the
proportion of patients who achieved a complete remission. Efficacy and safety analyses
included all patients who received at least one dose of quizartinib (ie, the intention-to-treat
population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy
were included in efficacy analyses by response; all other patients were considered to have
an unknown response. This study is registered with ClinicalTrials.gov, number
NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41,
and is completed.
FINDINGS: Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled
(157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive
patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete
remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative
patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive
patients achieved composite complete remission with five (4%) achieving complete
remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite
complete remission with one (3%) achieving complete remission. Across both cohorts (ie,
the intention-to-treat population of 333 patients), grade 3 or worse treatment-related
treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76
[23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected
using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]),
leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious
adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of
333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia
(40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related),
sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related).
Notable serious adverse events occurring in less than 5% of patients were torsades de
pointes (one [<1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died
within the study treatment period, including the 30-day follow-up. 18 (5%) patients died
because of an adverse event considered by the investigator to be treatment related (ten
[6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2.
INTERPRETATION: Single-agent quizartinib was shown to be highly active and generally
well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly
those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver
mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy
to help improve clinical outcomes in patients with very few options. Phase 3 studies
(NCT02039726; NCT02668653) will examine quizartinib at lower starting doses.
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